Journal article
Safety of Long-Acting β-Agonists Are New Data Really Required?
Abstract
Despite 20 years of debate, several US Food and Drug Administration (FDA) hearings, black-box warnings, and many descriptive articles and metaanalyses, controversy regarding the safety of long-acting beta-agonist (LABA) treatment in asthma patients continues. This has resulted in a recent call for another large and definitive safety study. This commentary focuses first on data provided in the metaanalysis recently undertaken by the FDA of …
Authors
Sears MR
Journal
CHEST Journal, Vol. 136, No. 2, pp. 604–607
Publisher
Elsevier
Publication Date
August 2009
DOI
10.1378/chest.09-1214
ISSN
0012-3692
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Administration, InhalationAdrenal Cortex HormonesAdrenergic beta-AgonistsAlbuterolAsthmaDelayed-Action PreparationsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationDrug-Related Side Effects and Adverse ReactionsFemaleHumansMaleNeeds AssessmentRandomized Controlled Trials as TopicRespiratory Function TestsRisk AssessmentSalmeterol XinafoateSeverity of Illness IndexSurvival RateUnited StatesUnited States Food and Drug Administration